SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development...
-- Article outlines advantages and provides further data to support the use of COLVERA for assessing response to treatment and...
SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased...
Pays off SWK Facility; Reduces Interest Going ForwardTORONTO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or...
STRATHROY, Ontario, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE;...
NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced...
Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies...
Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA),...
AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021 The press release published yesterday at 08.00 CET...
Coloplast A/S (“Coloplast” or the “Company”) is initiating a share buyback programme totalling up to DKK 500 million, as announced...
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can...
Oslo (Norway), 18 February 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4...
Pratteln, Switzerland, February 18, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces full redemption of its senior unsecured convertible bonds (the 2017/22...
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program In a Phase 3 trial in patients refractory to...
VANCOUVER, British Columbia, Feb. 17, 2022 (GLOBE NEWSWIRE) -- (CSE: CLC) Christina Lake Cannabis Corp. (the “Corporation” or “Christina Lake”) announces...
CINCINNATI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a...
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with...
New board members bring a wealth of financial, strategy and global health expertiseNORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE)...
